Stock Market Result Update on Mphasis for 3QFY2011 with an Accumulate recommendation and a Target Price of `420 (12 months).
Mphasis reported dismal set of 3QFY2011 results with volume growth of 3.0% qoq - out of which only 1.3% is from normal operations, the rest 1.7% is derived due to several one-off items booked in revenue. At the CMP, the stock is trading at 10.9x FY2013E EPS of `36.4 with a strong cash position of `2,029cr, which warrants limited downside. We recommend an Accumulate rating on the stock.
Quarterly highlights: Mphasis reported revenue of US$290mn, up merely 2.9% qoq. In rupee terms also revenue growth was 2.9% qoq with revenues at `1,294cr. These revenues include one-time revenues of `66.5cr. Also, `34.6cr of revenues were not booked in this quarter due to incomplete documentation. Adjusting for all this, revenues came in at `1,262cr, up merely 1.2% qoq. Mphasis reported 31bp qoq expansion in its EBITDA margin to 19.4%. However, the company did provision reversal of `11.0cr in employee costs and `15.6cr in S&M expenses. Adjusting for these reversals and one offs in revenues, EBITDA margin came in at 15.3% vs. 16.3% in 2QFY2011.
Outlook and valuation: The open billable positions in the application business declined from 1,000 to 825. However for the ITO business, it remained flat at 600. This highlights that growth in ITO remains intact and would continue to be the possible growth driver for the company. Going forward, management expects the direct channel (33% to revenue) and HP non-enterprise solution business (which is currently ~5% of revenue from HP channel) to drive growth, whereas the HP-ES business is expected to remain sluggish. We expect revenue growth will be muted at 2.7% yoy for FY2011E considering that in 1QFY2011 revenue run rate fell by 10% qoq as well as company’s revenue for 2QFY2011 and 3QFY2011 were driven by one-offs. However, the above-mentioned growth drivers are expected to result in the company’s revenue to record a 10% CAGR over FY2011–13E. We recommend Accumulate rating on the stock with a target price of `420, valuing it at 11.5x FY2013E EPS.